



Konferencja z okazji  
Międzynarodowego Dnia Badań Klinicznych 2017

## **BADANIA KLINICZNE: *porozmawiajmy o innowacjach***



Dostępność nowoczesnych terapii, – dokąd  
zmierzamy i co nas czeka w przyszłości?  
*Availability of modern therapies – where we are  
heading and what's the future?*

Nick Sykes  
Senior Director, Pfizer  
(on behalf of EFPIA)

# About EFPIA and CTR 536/2014

*The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world*


“ EFPIA sees the implementation of the Clinical Trials Regulation as an opportunity to demonstrate Europe’s commitment to clinical innovation, scientific collaboration and transparency of clinical trials information. Successful implementation of EU CTR is one of EFPIA’s priorities.

”

# Aim of today's presentation

- Outlining challenges in clinical development of new drugs
- Providing an overview of some of the ways we are changing how we manage and run clinical trials
- Addressing some of the challenges and highlighting the opportunities

# Challenging global medicine development environment



# Rising to the Challenge

- ✓ Making crisp, objective decisions
- ✓ Allocating resources appropriately
- ✓ Looking for 'early signs of clinical activity' & "Killer" experiments
- ✓ Increasing Phase 2 success Rates
- ✓ Improving cycle time
- ✓ Seeking expedited pathways

**Results being seen: Recent big 'game-changers':**

- Cures for Hepatitis C
- Immuno-oncology

# Current Challenges in Clinical Development: Solutions being Adopted

- Greater efficiencies in running trials using innovative trial design approaches and technology
- Move towards a patient-centered approach to drug development
  - Personalized treatments
  - Drug-diagnostic co-development
- Research and care need to be better integrated, anticipating real life implementations

# Adaptive Clinical Trial Design

**Many designs  
possible**

Sample Size Re-  
estimation

Bayesian  
Borrowing

Seamless Phase

Dose Allocation

Dose Selection

Model-Based  
Dose Escalation

Group Sequential


Population  
Enrichment

# Paving the Way for Innovation

Will the EU Clinical Trial regulation meet its stated objective of quicker access to new and innovative medicines?




# Regulatory Guidance




- ⇒ Sharing experiences between Member States
- ⇒ **EU guidance could be updated to get alignment between MSs and between EMA and MSs**
- ⇒ In addition, possible ICH guidance


# Strategic Planning




# Timing for Changes




# Transparency




# Adaptive Trials: To Sum Up




# The Changing Clinical Research Pathway: Towards a Life-Cycle Approach to Evidence Generation



# Sustainable Model of Drug Development – Efficiencies through Patient Selection




# Example of 21st century personalized medicine trial



Such projects are at the edge of several regulations:  
Clinical trials, data protection and IVD




# Fragmentation of the regulatory framework in Europe: a major bottleneck




# Streamline - Simplify - Harmonize

Europe must build an integrated and harmonized legal and ethical framework to foster relevant international clinical research



# The Potential for Real World Data




MENU

TAGS: [Clinical Trials](#) | [Comparative Effectiveness](#) | [Gastrointestinal](#) | [ASK THE ANALYST](#)

## Takeda Enlists Real World Evidence To Boost Marketed Entyvio


09 May 2017 | NEWS



by John Davis  
[john.davis@informa.com](mailto:john.davis@informa.com)

### Executive Summary

Japan's Takeda says it has confirmed the benefits of its best-selling inflammatory bowel disease therapy Entyvio in US medical practice through the collection of real world evidence.




MENU

TAGS: [Clinical Trials](#) | [Comparative Effectiveness](#) | [Commercial](#) | [ASK THE ANALYST](#) | [EMAIL](#)

## Relvar/Breo "Real World" Asthma Benefits Help GSK – But Can't Remove Generic Threat

08 May 2017 | ANALYSIS




by John Davis  
[john.davis@informa.com](mailto:john.davis@informa.com)

### Executive Summary

Top-line data from a second patient group, asthmatics, in the Salford Lung Study indicate that switching from usual therapy to GSK's Relvar Ellipta improves symptoms, but the results may not be enough to encourage switching before generic Seretide/Advair takes hold.

# Real-World Data/Evidence is relevant throughout the drug development lifecycle



# Technology can help....

Advances such as electronic data capture, and prevalence of wi-fi connectivity are driving changes in how clinical trials are conducted and analysed



**FirstWord**  
PHARMA PLUS  
Your News. Your Way.

[New Report] Real World Data Capabilities: Benchmarking Pharma Companies - Stay ahead in the data race and download now

Home > My News > All News > All Insight, Analysis and Views > StoryWatch

**FirstView: Market Access Impact Reports**

Are barriers winning or losing? Giving you a detailed picture of doctors from prescribing you are losing market share to

## Pfizer to initiate study of smartphone app to help patients with lupus report symptoms

(Ref: Pfizer)  
May 9th, 2017  
By: Katie Bell  
Tags: [Top Story](#) [Apple](#) [Pfizer](#) [Lupus](#) [Internal Medicine](#) [Clinical Research \(R&D\)](#)

Pfizer announced Tuesday that a new smartphone app, which aims to enable patients with lupus to report on their fatigue and other symptoms in real time, will be evaluated through the non-interventional VALUE study. The trial is due to begin at the end of the month, with results expected in December. Freda Lewis-Hall, Pfizer executive vice president and chief medical officer, said "the current paper methods of collecting patient-reported data can be cumbersome and inconvenient...VALUE holds promise for 'in the moment' reporting of symptoms and may open the door to similar tools being used in Pfizer-sponsored clinical studies for lupus and other diseases."

Pfizer said it jointly developed the mobile app with the Lupus Research Alliance and Tata Consultancy Services using Apple's ResearchKit platform and "building on existing research tools that have been validated in lupus." Kenneth M. Farber, co-CEO of the Lupus Research Alliance, noted that the "app may enable more frequent and consistent reporting from patients, thus providing better information for care teams and empowering patients to take a larger role in developing future therapies."


0  
G+1  
0  
Like  
13  
Share  
Tweet  
Email  
Print

# Trends in Technology Helping in Clinical Trials

- Using patients own health data from other systems
  - Electronic health records
  - Data captured on their own smartphone
- Making research participation more accessible
  - Self-reporting and tracking using technology in their pocket
  - Wearable sensors capturing data and transmitting the data to a remote location

# Challenges remain...

Reaching the potential :



# In Summary – Many opportunities to maximise efficiency

- Novel approaches to running/managing clinical trials are being adopted
  - Innovative trials designs
  - Patient-focussed approaches
  - Use of real-world data
  - Advances in technology
- Hurdles still to overcome
  - Legislative
  - Ensuring quality
  - Subjective



# Questions

